期刊文献+

曲妥珠单抗相关心脏毒性1例并文献复习 被引量:2

Cardiac toxicity induced by trastuzumab in a patient with breast cancer and literature review
下载PDF
导出
摘要 1例45岁女性患者因确诊"左乳腺恶性肿瘤",FISH检测HER-2阳性,在吡柔比星化疗6次后行紫杉醇+曲妥珠单抗化疗,曲妥珠单抗起始周期为7 d(4 mg·kg-1),化疗2次后周期改为21 d(6 mg·kg-1),6个月后改为曲妥珠单抗单药21 d方案化疗,18个月后患者出现胸闷、憋气症状,活动后明显,伴有双下肢水肿,心脏超声提示LVEF值33%。考虑该患者出现心功能不全与曲妥珠单抗的心脏毒性很可能相关。停用曲妥珠单抗化疗,予以去乙酰毛花甙强心、托拉塞米利尿、左卡尼汀营养心肌等治疗10 d,患者症状完全消失,LVEF值恢复至45%,4个月后复查LVEF值恢复至51%。 One case of 45-year-old female patient diagnosed as left breast cancer with positive FISH detection of HER-2 underwent chemotherapy with paclitaxel and trastuzumab after 6 times of chemotherapy with pirarubicin. The initial therapy period of trastuzumab was 7 days (4 mg·kg-1) and changed to 21 days (6 mg·kg-1) after 2 chemotherapies. Six months later, the chemotherapy was changed to trastuzumab with the cycle for 21 days. Eighteen months later, the patient developed chest tightness and breathlessness with lower extremity edema, which was obvious after activities. Cardiac ultrasound showed the LVEF value was 33%. Cardiac dysfunction induced by trastuzumab was considered and the chemotherapy of trastuzumab was stopped. Deacetylase lanatoside, torasemide diuretic and levocarnitine were given for improving heart function, diuresis and nutrition myocardium for 10 days. Then the symptom disappeared, LVEF value recovered to 45%. After 4 months, LVEF value recovered to 51%.
出处 《中国药物应用与监测》 CAS 2013年第6期359-361,共3页 Chinese Journal of Drug Application and Monitoring
关键词 乳腺癌 曲妥珠单抗 心脏毒性 药品不良反应 Breast cancer Trastuzurnab Cardiac toxicity Adverse drug reaction
  • 相关文献

参考文献9

  • 1Chen T,Xu T,Li Y. Risk of cardiac dysfunction with trastuzumab in breast cancer patients:a meta-analysis[J].{H}Cancer Treatment Reviews,2011,(04):312-320.
  • 2盛李明,杜向慧.乳腺癌患者赫赛汀相关心脏毒性机制及处理[J].中国临床药理学与治疗学,2011,16(9):1077-1080. 被引量:8
  • 3Rohrbach S,Niemann B,Silber RE. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation[J].{H}Basic Research in Cardiology,2005,(03):240-249.
  • 4Pentassuqlia L,Graf M,Lane H. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myoifbrillar structural damage without cell death in adult rat cardiomyocytes[J].{H}Experimental Cell Research,2009,(07):1302-1312.
  • 5Morris PG,Chen C,Steingart R. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose dense chemotherapy incorporating trastuzumab and lapatinib[J].{H}Clinical Cancer Research,2011,(10):3490-3499.
  • 6Van Hasselt JG,Boekhout AH,Beijnen JH. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity[J].{H}Clinical Pharmacology & Therapeutics,2011,(01):126-132.
  • 7Goldhirsch A,Gelber RD,Piccart-Gebhart MJ. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer(HERA):an open-label,randomised controlled trial[J].{H}LANCET,2013,(9897):1021-1028.
  • 8Costa RB,Kurra G,Greenberg L. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer[J].{H}ANNALS OF ONCOLOGY,2010,(11):2153-2160.
  • 9Pinto AC,Ades F,de Azambuja E. Trastuzumab for patients with HER2 positive breast cancer:delivery,duration and combination therapies[J].{H}BREAST,2013,(Suppl 2):S152-S155.

二级参考文献23

  • 1Cuadros M, Cano C, L6pez FJ, et al. HER2 status in breast cancer., experience of a Spanish National Reference Centre [J]. Clin Transl Oncol, 2011, 13 (5) : 335-340.
  • 2Spielmann M, Roch H, Delozier T, et al. Trastu- zumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial[J].J Clin Oncol, 2009, 27(36) : 6129-6134.
  • 3Slamon D, Eiermann W, Robert NPT, et al. BCIRG 006 Phase III Trial Comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis[J]. Cancer Res, 2009, 29 abstract 62.
  • 4Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial [J]. J Clin Oncol, 2008, 26(8): 1231-1238.
  • 5Rastogi P, Jeong J, Geyer CE, et al. Five year up- date of cardiac dysfunction on NSABP B-31, a ran- domized trial of sequential doxorubicin/cyclophos- phamide (AC)→paelitaxel (T) vs. AC→T with trastuzumab (H) [J]. J Clin Oncol, 2007, 25 (18S) : LBA513.
  • 6Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial [J].J Clin Oncol, 2007, 25(25): 3859-3865.
  • 7Chen T, Xu T, Li Y, et al. Risk of cardiac dys- function with trastuzumab in breast cancer patients: a meta-analysis [J]. Cancer Treat Rev, 2011, 37 (4) : 312-320.
  • 8Rohrbach S, Niemann B, Silber RE, et al. Neureg- ulin receptors erbB2 and erbB4 in failing human my- ocardium-depressed expression and attenuated acti- vation [J].Basic Res Cardiol, 2005, 100(3) : 240 -249.
  • 9Chien KR. Herceptin and the heart--a molecular modifier of cardiac failure[J]. N Engl J Med, 2006, 354(8): 789-790.
  • 10Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity., biological hypotheses and clinieaI open issues [J]. Expert Opin Biol Ther, 2008, 8 (12): 1963-1971.

共引文献7

同被引文献20

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部